Barbara Ryan
Barbara Ryan's purchase track record
How the stock did after each of Barbara Ryan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/9/2026 | INDV | $1K | +14.7% | +5.3% | +12.9% |
| 1/5/2026 | INDV | $27K | -16.1% | +10.3% | +9.2% |
| 6/1/2022 | IVF | $10K | +6.4% | +7.6% | -0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Indivior reports Sublocade sales growth and higher profitability. Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.
Transaction History
| INKT | ▲ Buy | Grant | 1,622 | $18K | 9/1/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 500 | $6K | 6/4/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 1,000 | $13K | 6/4/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,434 | $18K | 6/1/2026 | View on chart |
| INDV | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 | View on chart |
| INDV | ▲ Buy | Open Market | 8 | $249 | 3/13/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 300 | $5K | 3/10/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 500 | $8K | 3/10/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 500 | $8K | 3/10/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 200 | $2K | 3/9/2026 | View on chart |
| INDV | ▲ Buy | Open Market | 31 | $1K | 3/9/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 100 | $1K | 3/2/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,629 | $18K | 3/2/2026 | View on chart |
| INKT | ▼ Sell | Open Market | 400 | $4K | 2/27/2026 | View on chart |
| INDV | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 | View on chart |
| INDV | ▲ Buy | Open Market | 775 | $27K | 1/5/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,601 | $18K | 12/1/2025 | View on chart |
| INKT | ▲ Buy | Grant | 1,281 | $18K | 9/2/2025 | View on chart |
| INKT | ▲ Buy | Grant | 2,476 | $18K | 6/2/2025 | View on chart |
| INKT | ▲ Buy | Grant | 2,019 | $18K | 3/3/2025 | View on chart |
| INKT | ▲ Buy | Grant | 24,229 | $18K | 12/1/2024 | View on chart |
| INKT | ▲ Buy | Grant | 21,649 | $18K | 9/3/2024 | View on chart |
| INKT | ▲ Buy | Grant | 17,841 | $18K | 6/3/2024 | View on chart |
| INKT | ▲ Buy | Grant | 18,685 | $18K | 3/1/2024 | View on chart |
| INKT | ▲ Buy | Grant | 17,068 | $18K | 12/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 12,158 | $18K | 9/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 10,086 | $18K | 6/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 8,493 | $18K | 3/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 6,801 | $18K | 12/1/2022 | View on chart |
| INKT | ▲ Buy | Grant | 13,550 | $36K | 9/15/2022 | View on chart |
| IVF | ▲ Buy | Open Market | 10,526 | $10K | 6/1/2022 | View on chart |
| IVF | ▲ Buy | Grant | 8,588 | $0 | 1/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative
MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative. MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.